Biogen Inc.（BIIB）财务数据BIIBBiogen Inc.

Biogen Inc. (BIIB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Spinal Muscular Atrophy-SPINRAZA, accounting for 22.0% of total sales, equivalent to $601.70M. Other significant revenue streams include MS product revenues-TYSABRI and MS product revenues-Fumarate. Understanding this composition is critical for investors evaluating how BIIB navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Biogen Inc. maintains a gross margin of 65.46%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 20.16%, while the net margin is 3.56%. These profitability ratios, combined with a Return on Equity (ROE) of 4.58%, provide a clear picture of how effectively BIIB converts its operational activities into shareholder value.

In the context of the broader market, BIIB competes directly with industry leaders such as RPRX and HLN. With a market capitalization of $33.35B, it holds a significant position in the sector. When comparing efficiency, BIIB's gross margin of 65.46% stands against RPRX's 100.00% and HLN's 66.10%. Such benchmarking helps identify whether Biogen Inc. is trading at a premium or discount relative to its financial performance.

Biogen has shown solid revenue growth, with Q2 2026 revenue at $2.736 billion and a gross margin of 65.46%. The net income for Q2 2026 was $97.5 million, demonstrating profitability despite recent fluctuations.